Document is current
Any future updates will be listed below
-
Authors
Tarallo, Antonietta
Damiano, Carla
Strollo, Sandra https://orcid.org/0000-0001-5397-2928
Minopoli, Nadia https://orcid.org/0000-0003-1675-0538
Indrieri, Alessia https://orcid.org/0000-0002-2325-0913
Polishchuk, Elena
Zappa, Francesca
Nusco, Edoardo
Fecarotta, Simona
Porto, Caterina
Coletta, Marcella
Iacono, Roberta https://orcid.org/0000-0002-3586-4322
Moracci, Marco
Polishchuk, Roman https://orcid.org/0000-0002-7698-1955
Medina, Diego Luis https://orcid.org/0000-0002-7347-2645
Imbimbo, Paola
Monti, Daria Maria
De Matteis, Maria Antonietta https://orcid.org/0000-0003-0053-3061
Parenti, Giancarlo https://orcid.org/0000-0002-6287-5748
-
Funding
Funding for this research was provided by:
Associazione Italiana Glicogenosi
Zambon Pharma
Spark Therapeutics Inc
French Muscular Dystrophy Association (20852)
PON Dottorati Innovativi, MIUR
Fondazione Telethon
- License Information
-
More Information
Article History
Received: 15 April 2021
Revised: 15 September 2021
Accepted: 20 September 2021
First Online: 4 October 2021
Conflict of interest
: G.P. received honoraria or travel reimbursement from TAKEDA, Sanofi‐Genzyme, and Orchard therapeutics. This work was supported in part by Spark Therapeutic Inc.
